Article Text

Download PDFPDF
Pseudomyxoma peritonei: the ‘controversial’ disease
  1. E. Galani,
  2. G. M. Marx,
  3. C. B. Steer,
  4. G. Culora and
  5. P. G. Harper
  1. Medical Oncology Department, Guy's Hospital, London, UK
  1. Address correspondence and reprint requests to: Dr. Eleni Galani, MD, Clinical Research Fellow, Medical Oncology Department, Guys Hospital, St Thomas St, SE1 9RT, London, UK. Email: eleni.galani{at}


Pseudomyxoma peritonei (PMP) is a rare disease that is characterized by a large amount of mucinous ascites with peritoneal and omental implants. The etiology of the disease remains unclear. Histologically, two main categories have been described: disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis (PMCA). It is commonly diagnosed incidentally at laparotomy. Most investigators agree that radical surgical debulking and appendectomy are the cornerstone of treatment, but the optimal management of the disease remains controversial. The role of intraoperative and intraperitoneal chemotherapy has been evaluated by a number of authors. The clinical outcomes vary widely between the benign and the malignant forms and between the different treatment modalities. We discuss the pathology, origin, clinical presentation, diagnosis, treatment, and prognosis of PMP.

  • intraperitoneal chemotherapy
  • mucinous ascites
  • pseudomyxoma peritonei

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.